We investigated the in vitro effects of high energy shock wave alone or combined with anticancer drug treatment on an established human bladder cancer cell line, KK-47 cells. Exposure of the cell suspensions to 500-2,500 shock waves, generated with the EDAP lithotriptor LTO1 resulted in reduced cell viability with an increasing number of shock doses. DNA flow cytometric analysis revealed a marginal effect on the G2+M and S phases of the cell cycle. When shock wave-treated cells were exposed to mitomycin C, cisplatin, methotrexate or adriamycin, an additive cytotoxic effect was obtained at all shock doses. Adriamycin showed the highest additive effect of the drugs tested. Significant increases in glutamic oxaloacetic transaminase, alkaline phosphatase, creatine phosphokinase and lactate dehydrogenase concentrations in the nutrient medium were observed at over 400 shock doses, reflecting damage to the cell membrane. These data suggest that high energy shock wave may be applicable in combination with some anticancer drugs in the treatment of transitional cell carcinoma.

Keywords:
High energy shock wave, Bladder cancer cells, Enzymes Cell viability, Cell cycle, Anticancer drugs
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.